What the FDA labels say about taking them together
Omeprazole and tocilizumab
Tocilizumab's FDA label of December 16, 2025 names omeprazole in its drug interactions section; the omeprazole labels PlainMeds reads (2) do not name tocilizumab. The tocilizumab label: “In vivo studies with omeprazole, metabolized by CYP2C19 and CYP3A4, and simvastatin, metabolized by CYP3A4, showed up to a 28% and 57% decrease in exposure one week following a single dose of ACTEMRA, respectively.”
Check it at the source: the omeprazole FDA label on DailyMed (effective April 22, 2024, Apotex Corp); the tocilizumab FDA label on DailyMed (effective December 16, 2025, Genentech, Inc.).
What does the omeprazole label say about tocilizumab?
Omeprazole's label (effective April 22, 2024) and its 1 other brand-application label do not name tocilizumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Omeprazole), Apotex Corp, effective April 22, 2024 (SPL set b83329ac-a65e-b3af-a3fb-c5a6c740e5e7), via openFDA; the full label on DailyMed
What does the tocilizumab label say about omeprazole?
Tocilizumab label, drug interactionsIn vivo studies with omeprazole, metabolized by CYP2C19 and CYP3A4, and simvastatin, metabolized by CYP3A4, showed up to a 28% and 57% decrease in exposure one week following a single dose of ACTEMRA, respectively.
Source: FDA drug label (Avtozma, BLA761420), CELLTRION USA, Inc., effective July 27, 2026 (SPL set 581c288f-8015-40ef-a4c3-683c96db193d), via openFDA
Source: FDA drug label (ACTEMRA), Genentech, Inc., effective December 16, 2025 (SPL set 2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Omeprazole | Tocilizumab | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | Rheumatoid arthritis, COVID-19 |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0295 per capsule 20 mg capsule | $821.00 per mL 162 mg/0.9 mL autoinjct |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once